Atea Pharmaceuticals (NASDAQ:AVIR) said it remains on track for two key Phase 3 hepatitis C readouts in 2026 while advancing a newer hepatitis E program aimed at immunocompromised patients with no approved treatment options.
During the company’s first-quarter 2026 earnings call, Chief Executive Officer and Founder Dr. Jean-Pierre Sommadossi described the year as “catalyst rich” for Atea, citing upcoming top-line data from the company’s global Phase 3 hepatitis C virus, or HCV, program. The company is evaluating a combination regimen of bemnifosbuvir and ruzasvir against the current standard of care, sofosbuvir/velpatasvir, marketed as Epclusa.
